About PrimeraDx
PrimeraDx is a company based in Mansfield (United Kingdom) founded in 2004 was acquired by Qiagen in March 2014. PrimeraDx has raised $19.76 million across 4 funding rounds from investors including Qiagen, HHS and Abingworth. PrimeraDx offers products and services including ICEPlex System, Companion Diagnostics, Instrumentation, Software, and Consumables. PrimeraDx operates in a competitive market with competitors including Ansa Biotechnologies, Nuclera Nucleics, NeuMoDx, Twist Bioscience and GenMark Diagnostics, among others.
- Headquarter Mansfield, United Kingdom
- SectorsHealthcare
- Website primeradx.com
- Social LinkedIn X
- Acquired by Qiagen (Mar 2014)
- Legal Name Primeradx, Inc.
Products & Services of PrimeraDx
PrimeraDx offers a comprehensive portfolio of products and services, including ICEPlex System, Companion Diagnostics, Instrumentation, Software, and Consumables.
Quantitative PCR system for multiplexed clinical assays.
Products for developing diagnostic tests with pharmaceuticals.
Tools for PCR and capillary electrophoresis in research.
Applications for managing PCR diagnostic processes.
Materials for PCR assays and diagnostics.
Funding Insights of PrimeraDx
PrimeraDx has successfully raised a total of $19.76M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $335.19 thousand completed in September 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.76M
- Total Rounds 4
- Last Round Grant — $335,186
- First Round $1.15M
(Sep 2009)
- Investors Count 8
All 4 funding rounds of PrimeraDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2012 | $335,186 | Grant | – | – | |
| May 2011 | $2.8M | Grant | – | – | |
| Sep 2009 | $19.76M | Series B | – | Abingworth, InterWest Partners | – |
| Sep 2009 | $1.15M | Debt – Conventional | – | – | – |
9 investors in total: 9 institutional.
Investors in PrimeraDx
PrimeraDx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiagen, HHS and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Early stage healthcare services investments are facilitated by CHL. | – | chlmedical.com | Westport, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for PrimeraDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PrimeraDx
4 dated milestones of PrimeraDx across 10 years, from founding to its latest funding, stage changes and deals.
- Founded PrimeraDx is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $335K.
- Exit Acquired by Qiagen.
Competitors of PrimeraDx
PrimeraDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ansa Biotechnologies, Nuclera Nucleics, NeuMoDx, Twist Bioscience and GenMark Diagnostics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ansabio.com | 2017 | Berkeley, United States | $175.5M | 253 | DNA synthesis technology using enzymes is provided. | |
| nuclera.com | 2013 | Cambridge, United Kingdom | $164.2M | 134 | Desktop bioprinter for genes and proteins production is developed. | |
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| alveotechnologies.com | 2014 | Alameda, United States | $63.61M | – | Cloud-powered POC MDx device | |
| biomeme.com | 2013 | Philadelphia, United States | $6.2M | 202 | Smartphone-based DNA detection platform is developed for diagnostics. | |
| sense-bio.com | 2014 | Abingdon, United Kingdom | $79.22M | 43 | Provider of point of care molecular diagnostics solutions | |
| mesabiotech.com | 2009 | San Diego, United States | $26.8M | 131 | Point-of-care molecular diagnostic kits are developed and supplied. | |
| dnascript.com | 2014 | Paris, France | $301.69M | – | Benchtop DNA printers for nucleic acid synthesis are developed. |
Detailed competitors of PrimeraDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Primeradx
Complete news archive for PrimeraDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PrimeraDx
10 companies that operate in the same segment as PrimeraDx (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PrimeraDx
PrimeraDx was founded in 2004 and raised its 1st funding round 5 years after it was founded.
PrimeraDx is headquartered in Mansfield, United Kingdom. It is registered at Mansfield, England, United Kingdom.
PrimeraDx is a funded company, having raised a total of $19.76M across 4 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.15M, raised on Sep 2009.
PrimeraDx was founded in 2004 in Mansfield, United Kingdom, within the molecular diagnostics sector. A platform and companion assays are developed for quantitative multiplex molecular diagnostics. These tools are designed to support highly multiplexed clinical solutions. Operations center on enabling precise, quantitative testing for medical applications across various diagnostic needs.
PrimeraDx's top competitors include Nuclera Nucleics, GenMark Diagnostics and Twist Bioscience.
PrimeraDx offers ICEPlex System, Companion Diagnostics, Instrumentation, Software, and Consumables.
PrimeraDx has 9 investors. Key investors include Qiagen, HHS, Abingworth, Burrill and Company, and InterWest.
PrimeraDx operates through Primeradx, Inc..
Yes. PrimeraDx was acquired by Qiagen in March 2014.